Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161711 | 0.88 | BCHE (0.43) | EPHX2EPHX1FUCA1BCHESPHK2 | |
| SCHEMBL21302824 | 0.78 | NAAA (0.49) | CASP2NAAAEPHX1FUCA1FAAH | |
| SCHEMBL21302827 | 0.78 | NAAA (0.49) | CASP2NAAAEPHX1FUCA1FAAH | |
| SCHEMBL20161323 | 0.77 | NAAA (0.47) | CASP2NAAAEPHX2EPHX1FUCA1 | |
| SCHEMBL20161560 | 0.77 | NAAA (0.47) | CASP2NAAAEPHX2EPHX1FUCA1 | |
| SCHEMBL21342122 | 0.75 | THRB (0.33) | — | |
| SCHEMBL18214231 | 0.74 | GBA2 (0.48) | NAAAFAAHSPHK2SPHK1 | |
| SCHEMBL20161280 | 0.73 | EPHX1 (0.41) | EPHX2EPHX1 | |
| SCHEMBL11241003 | 0.73 | SPHK2 (0.69) | SPHK2SPHK1 | |
| SCHEMBL11114512 | 0.73 | SPHK2 (0.69) | SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | CASP2 4438/4885NAAA 232/4885EPHX2 1855/4885 |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | KRT18, CUTA, GLA | CASP2 4438/4885NAAA 232/4885EPHX2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.